Weiping Liu

机构：Peking University, Southern University of Science and Technology, Peking University Cancer Hospital, China Institute of Atomic Energy, Ministry of Education · ORCID：0000-0002-0367-1411

发表论文 298 篇 · 总被引 5484 次 · h-index 36

代表论文

• Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial (2025 · Nature Medicine · 被引 124)
• Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicenter analysis in China (2025 · Cancer Letters · 被引 15)
• Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial (2024 · Blood · 被引 12)
• OA-63 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study (2024 · Clinical Lymphoma Myeloma & Leukemia · 被引 8)
• Secular trends of dental caries and association with nutritional status: a retrospective analysis of 16,199 Chinese students from three successive national surveys from 2010 to 2019 (2024 · Frontiers in Public Health · 被引 8)
• Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial (2025 · Nature Medicine · 被引 7)